Brian Hogan, MD
Neurology · Tuscaloosa, ALNPI 1679677298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,973 of the $123,460 with a category attached, or 73.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.7%. Reporting peaked in 2022 at $26,995 and has fallen 81.7% since, to $4,940 in 2025. Among neurology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,508 payments — averaging $81.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Amgen$24K
- Biohaven Pharmaceutical Holding Company Ltd.$21K
- Biohaven Pharmaceuticals, Inc.$20K
- Teva Pharmaceuticals USA, Inc.$13K
- UCB, Inc.$3K
- plus $17K from 54 others
What the payments were for
- Consulting fees$1,7701%
- Speaking & faculty fees$90,97374%
- Travel & lodging$4,3163%
- Food & beverage$26,19521%
- Education$2050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$39,170
- AIMOVIG$22,827
- UBRELVY$21,969
- QULIPTA$12,719
- AJOVY$11,353
- Briviact$950
- Nayzilam$570
- UPLIZNA$218
- PURIFIED CORTROPHIN GEL$205
- Leqembi$104
How this compares
$123,460 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 16 | $630,746 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 40 | $550,381 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 40 | $148,153 |
| NuplazidPimavanserin Tartrate | 28 | $137,209 |
| CopaxoneGlatiramer Acetate | 24 | $135,467 |
| Nurtec OdtRimegepant Sulfate | 101 | $132,325 |
| UbrelvyUbrogepant | 74 | $112,702 |
| QuliptaAtogepant | 88 | $107,707 |
| Kesimpta PenOfatumumab | 12 | $97,625 |
| BriviactBrivaracetam | 54 | $87,574 |
| VimpatLacosamide | 32 | $67,601 |
| Aimovig AutoinjectorErenumab-Aooe | 64 | $60,648 |
| FycompaPerampanel | 51 | $58,459 |
| Emgality PenGalcanezumab-Gnlm | 56 | $54,768 |
| GlatopaGlatiramer Acetate | 25 | $54,696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Dilantin | $1,204 | $687,427161 claims |
| AbbVieUbrelvy, Qulipta, Botox | $25,602 | $261,103188 claims |
| UCB, Inc.Briviact, Vimpat, Neupro | $2,908 | $178,181110 claims |
| Grifols USA, LLCGamunex-C | $430 | $148,15340 claims |
| Acadia Pharmaceuticals IncNuplazid | $457 | $137,20928 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $12,603 | $135,46724 claims |
| Eisai Inc.Fycompa | $681 | $58,45951 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $453 | $39,32730 claims |
| MDD US Operations, LLCGocovri | $104 | $39,11112 claims |
| SK Life Science, Inc.Xcopri | $570 | $35,26831 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $165 | $4,78327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 neurology providers in Alabama.
Other neurology in Tuscaloosa
- Timothy PrestleyTuscaloosa$210K
- Thomas EmigTuscaloosa$27K
- Thomas PattonTuscaloosa$20K
- Diane CounceBirmingham$895K
- Daniel DeesMobile$799K
- Christopher LagankeCullman$711K
- Hayden LongMobile$386K
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Emily RiserBirmingham$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.